What are the 15 pharmaceutical stocks with the potential to double (list attached)
The 15 pharmaceutical stocks with the potential to double. Pharmaceutical leading stocks refer to leading companies in the pharmaceutical industry. With strong R&D, production and sales capabilities, relying on excellent product quality and innovative drug research and development capabilities, the editor below brings 15 pharmaceutical stocks with the potential to double. Let's take a look, hoping to bring reference.
15 Pharmaceutical stocks with the potential to double (list attached)
1. Hengrui Pharmaceuticals (Chemical Pharmaceuticals)
Current price: 40.95, total market value: 261.9 billion, circulation market value: 261.2 billion, third quarter of 2021: 0.66
Theme concept: Domestic chemical pharmaceuticals, innovative drugs leader. A-share pharmaceutical stock with the largest market capitalization.
Main business: drug research and development, production and sales.
2. Huahai Pharmaceutical (Chemical Pharmaceuticals)
Current price: 20.99, total market value: 31.3 billion, circulating market value: 30.5 billion, third quarter of 2021: 0.41
Theme concept: A leading company in the domestic specialty API industry, it is the world's largest provider of prici and sartan drugs.
Main business: manufacturing and sales of tablets, hard capsules, APIs, and pharmaceutical intermediates.
3. Tonghua Dongbao (Chemical Pharmaceuticals)
Current price: 10.15, total market value: 20.6 billion, circulating market value: 20.6 billion, third quarter of 2021: 0.52
Theme concept: Domestic leading insulin stocks.
Main business: production and sales of Chinese and Western patent medicines, biological products and plastic building materials.
4. WuXi AppTec (Pharmaceutical R&D)
Current price: 104.80, total market value: 309.8 billion, circulating market value: 266.9 billion, third quarter of 2021: 1.22
Theme concept: CXO is the leader in the complete industrial chain, pre-clinical CRO for small molecule drugs, and ranks first in domestic chemical pharmaceutical CMO.
Main business: The main business is an all-round, integrated platform service for the discovery, development and production of small molecule chemical drugs. It provides various new drug services to global pharmaceutical companies in the form of a full industry chain platform. R&D, production and supporting services; in addition, the issuer also provides overseas medical device testing and overseas precision medical R&D and production services.
5. Zhaoyan New Drug (Pharmaceutical Research and Development)
Current price: 96.88, total market value: 36.9 billion, circulation market value: 31 billion, third quarter of 2021: 0.95
Theme concept: leading drug non-clinical safety, drug preclinical research services.
Main business: drug preclinical research services focusing on drug non-clinical safety evaluation services and sales of experimental animals and ancillary products.
6. Mindray Medical (Medical Devices)
Current price: 323.28, total market value: 393 billion, circulation market value: 393 billion, third quarter of 2021: 5.48
Theme concept: Domestic medical device leader.
Main business: Engaged in the research and development, manufacturing, marketing and services of medical devices. We are always customer-oriented and committed to providing high-quality products and services to medical institutions around the world.
7 , Kailitech (Medical Devices)
Current price: 9.10, total market value: 6.553 billion, circulation market value: 6.521 billion, third quarter of 2021: 0.28
Theme concept: vertebroplasty micro A leader in invasive interventional surgery systems and orthopedic surgical instruments.
Main business: R&D, production and sales of minimally invasive interventional vertebroplasty surgery systems.
8. Shouxiangu (Chinese patent medicine)
Current price: 52.46, total market value: 8 billion, circulation market value: 8 billion, third quarter of 2021: 0.58
Theme concept: Domestic Ganoderma lucidum leader.
Main business: engaged in the selection, cultivation, processing and sales of precious Chinese medicinal materials such as Ganoderma lucidum and Dendrobium officinale.
9. Taiji Group (Chinese Patent Medicine)
Current price: 18.86, total market value: 10.5 billion, circulation market value: 10.5 billion, third quarter of 2021: 0.45
Theme concept: One of the leading Chinese patent medicines, the leader of the Chinese patent medicine sector in the early stage, and its performance has greatly increased expectations.
Main business: production and sales of Chinese patent medicines, Western medicines, health care products, medical packaging products, medical devices, and import and export of raw materials, Chinese herbal medicines, and medicinal packaging.
10. Jiangzhong Pharmaceutical (Chinese patent medicine)
Current price: 11.81, total market value: 7.440 billion, circulation market value: 7.373 billion, third quarter of 2021: 0.72
Theme concept: Jiangzhong brand Jianweixiaoshi tablets, one of the leading Chinese patent medicines and a long-established OTC company.
Main business: engaged in the production, research and development and sales of pharmaceuticals and general health products.
11. Tongce Medical (Medical Services)
Current price: 11.81, total market value: 47.6 billion, circulating market value: 47.6 billion, third quarter of 2021: 1.93
Theme concept: Domestic leading dental medical stocks.
Main business: investment management, operation of medical equipment, import and export business, technology development, technical consulting, technical training and technical services, and all other legal projects that do not require approval
12. Weining Health (Medical Services)
Current price: 11.51, total market value: 24.7 billion, circulation market value: 20.8 billion, third quarter of 2021: 0.12
Theme concept: Domestic leading stock of medical informatization (cloud platform).
Main business: The company is mainly engaged in medical software research and development, sales and technical services, and provides overall solutions for the informatization of the medical and health industry.
13. Xinghu Technology (new crown specific drug concept)
Current price: 5.78, total market value: 4.272 billion, circulation market 4.272 billion, third quarter of 2021: 0.108
Theme concept: asset injection, COVID-19 specific medicine, and expected performance growth. Sichuan Jiuling Pharmaceutical, a wholly-owned subsidiary, is currently the largest API manufacturer of anti-HIV drug ritonavir in China. Ritonavir is an important API for Pfizer’s new coronavirus oral specific drug.
Main business: production and sales of chemical raw materials, nucleoside (acid) and amino acid biochemical products; edible flavorings, seasoning products, etc.
14. Dayang Biotechnology (new crown specific drug concept)
Current price: 34.58, total market value: 2.075 billion, circulating market value: 1.407 billion, third quarter of 2021: 1.16
Theme concept: An important raw material for Pfizer's new crown drug, ethyl trifluoroacetate, is produced by an enterprise, and the price is relatively high.
Main business: engaged in the production and sales of chemical raw material products such as inorganic salts and veterinary raw materials.
15. Frontier Bio (New Crown Special Drug Concept)
Current price: 15.92, total market value: 5.727 billion, circulating market value: 2.993 billion, third quarter of 2021: -0.49
Theme concept: The company’s new injectable anti-COVID-19 drug FB2001 has launched Phase 1 clinical trials in the United States and has been approved to conduct Phase 1 clinical bridging trials in China.
Main business: Committed to the research, development, production and sales of innovative drugs targeting major unmet clinical needs.
No recommendation or implication is made. Investment is risky, so please be cautious when entering the market.
What are the leading traditional Chinese medicine stocks?
The leading traditional Chinese medicine stocks are:
1. Yunnan Baiyao 000538: It is a company mainly engaged in chemical raw materials, chemical preparations, and traditional Chinese medicine. Companies that specialize in patent medicines, Chinese herbal medicines, and biological products rank first in the industry in terms of market capitalization at 82.197 billion yuan, with a price-to-earnings ratio of 24.28;
2. Pien Tze Huang 600436: is a company mainly engaged in tablets and tablets A company that produces and sells pharmaceutical products and tourism products such as pharmaceuticals and granules, its circulation market value ranks second in the industry at 64.283 billion yuan, and its price-to-earnings ratio reaches 39.74;
3. Baiyunshan 600332: Yes One of the most valuable pharmaceutical brands in China, its circulation market value ranks third in the industry at 42.494 billion yuan, with a price-to-earnings ratio of 11.46.
In addition, there are Tong Ren Tang 600085, Tasly 600535, Jichuan Pharmaceutical 600566, China Resources Sanjiu 000999, Dong'e Ejiao 000423, etc.
What are the leading stocks of API stocks?
The leading Chinese medicine stocks include Guangxin Pharmaceutical (300519), Xinzi Pharmaceutical (002118), Shenlong Rongfa (300534), Yunnan Baiyao (00538) ), Tong Ren Tang (600085), Pien Tze Huang (600436).
Extended information:
1. Other traditional Chinese medicine concept stocks include:
1. Taiantang: In the past 7 trading days, Taiantang fell 20.26 , the highest price was 6.48 yuan, and the total market value fell by 851 million yuan, a decrease of 20.26.
2. Yisheng Pharmaceutical: Looking back on the past 7 trading days, Yisheng Pharmaceutical has fallen for 6 consecutive days. It fell by 9.38 during the whole period, with the highest price of 8.58 yuan and the lowest price of 9.14 yuan. The final transaction volume was 40.1966 million lots.
3. Yiling Pharmaceutical: Yiling Pharmaceutical’s stock price fell by 15.08 in the last seven days, and rose by 2.26 in 2022, with a highest price of 25.76 yuan and a market value of 34.784 billion yuan.
2. Investment logic of traditional Chinese medicine companies:
With the continued support from the national policy level, the traditional Chinese medicine sector may be favored by market investors in the short term.
Innovation and consumption are the two main lines of the long-term development direction of the traditional Chinese medicine industry. At present, listed Chinese medicine companies that are doing relatively well include Yiling Pharmaceutical, which has strong traditional Chinese medicine innovation capabilities, and Yunnan Baiyao and Pien Tze Huang, which have strong general consumption attributes.
It is recommended to pay attention to the following transformation opportunities: transform into innovative traditional Chinese medicine R&D enterprises and use evidence-based medicine to develop clinically necessary drugs with excellent efficacy; transform the general consumer goods field of "medical insurance immunity" to find new growth points; transform low-income enterprises Suppliers of high-quality Chinese herbal medicines at low prices, especially artificial substitutes for scarce Chinese herbal medicine resources.
Three. Jiuzhitang: The company's predecessor, Laojiuzhitang Pharmacy, was founded in 1650. Jiuzhitang and Youbo trademarks are well-known trademarks in China; "Jiuzhitang" is recognized as a "Chinese time-honored brand" by the Ministry of Commerce; Jiuzhitang traditional Chinese medicine culture is included in the national intangible culture Heritage Conservation List.
What are the leading pharmaceutical manufacturing stocks?
The leading pharmaceutical manufacturing stocks are: 600085 Tong Ren Tang, 000538 Yunnan Baiyao, 600771 Tibet Pharmaceutical, 600285 Lingrui Shares, 000423 Dong'e Ejiao, 000650 Renhe Pharmaceutical, 600422 Kunming Pharmaceutical, 600771 Dongsheng Technology, 000597 Northeast Pharmaceutical, 600829 Sanjing Pharmaceutical, 600812 North China Pharmaceutical, 600488 Tianyao Shares, 002019 Xinfu Pharmaceutical, 600252 Zhongheng Group, 600276 Hengrui Pharmaceutical, 000952 Guangji Pharmaceutical Industry etc.
What are the leading pharmaceutical stocks?
The leading pharmaceutical stocks are:
1. Jingfeng Pharmaceutical: leading pharmaceutical stock. Announced on December 21, 2018, the company communicated with the U.S. FDA on the international multi-center phase III clinical trial of the company's anti-PD-1 antibody SHR-1210 combined with apatinib mesylate as first-line treatment of hepatocellular carcinoma. The trial will be held soon. Simultaneously launched in the United States, Europe and China.
2. Haixiang Pharmaceutical: a leading pharmaceutical stock. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. is a listed company controlled by Guangzhou Pharmaceutical Group Co., Ltd. (A shares 600332, H shares 00874), mainly engaged in, (1) Chinese and Western patent medicines, chemical raw materials, natural medicines, biomedicine, chemical raw materials Research, development, manufacturing and sales of intermediates; (2) Wholesale, retail and import and export business of Western medicines, traditional Chinese medicines and medical devices; (3) Research, development, production and sales of comprehensive health products; and (4) Medical services and health management , investment in health industries such as health care and elderly care, etc.
3. China Resources Sanjiu: a leading pharmaceutical stock. The profit of the pharmaceutical industry in 2015 is expected to be 260.2 billion yuan, a year-on-year increase of 11.9, and the growth rate will decline by 0.4 percentage points year-on-year.
4. Kunming Pharmaceutical Group: a leading pharmaceutical stock. Sinopharm plans to actively develop the e-commerce industry, expand to the mobile APP "Sinopharm Online", and add a "Sinopharm Online" channel to increase public attention on the Sinopharm Mall, respond to the loosening of online prescription drug sales, and start preparing for the BtoC model. Previously, Sinopharm Mall, a B2B pharmaceutical e-commerce trading platform independently developed and operated by the company, was officially launched for trial operation in October 2013. It has product categories such as medicines, food, oral supplies, family planning supplies, medical equipment, and cosmeceuticals.
5. Yaoshi Technology: a leading pharmaceutical stock. The leader in the domestic pharmaceutical outsourcing industry, it is the first CRO and CMO integrated company to engage in pharmaceutical R&D and production outsourcing in China. Its senior management team has more than 200 authorized and pending patents; its main business is small molecules An all-round, integrated platform service for the discovery, development and production of chemical drugs, providing global pharmaceutical companies with R&D, production and supporting services for various new drugs in the form of a full industry chain platform; the company also provides overseas medical device testing and overseas Precision medical research and development and production services.
Other pharmaceutical concept stocks include: Haichen Pharmaceutical, Beida Pharmaceutical, Changshan Pharmaceutical, Fuan Pharmaceutical, Zhendong Pharmaceutical, Huaren Pharmaceutical, Laimei Pharmaceutical, etc.